Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says

Law360, New York (May 10, 2013, 3:06 PM EDT) -- Aveo Pharmaceuticals Inc. was hit with a proposed class action Thursday accusing it of hiding that the U.S. Food and Drug Administration found that its kidney cancer treatment drug Tivozanib increased patients' risk of death more than competitors and that Aveo's trials for the drug were inadequate.

For more than a year, the Massachusetts drugmaker and its top executives led shareholders to believe that Tivozanib, also known as Tivopath, was likely to garner FDA approval, according to a complaint filed in Massachusetts federal court. But on...
To view the full article, register now.